Oral Screening Report

Oral Screening Report
Methodology
Methodology
148 volunteers were screened across two days at the Oncology Care Conference 2023 in
London using the OralID device (Forward Science). This device aids visualisation of
abnormalities of the oral mucosal such as cancer and pre-cancer by using fluorescence
technology. The blue light is at a wavelength of 435–460 nm, allowing it to fluoresce green
when shining on healthy tissue. When shining on abnormal tissue, the abnormality appears
dark blue due to to a lack of fluorescent activity. This allows the clinician to observe
abnormalities that may have otherwise been missed.
Symptoms and risk factors for disease
Prior to examination, volunteers were asked to complete a survey to identify their risk of oral
cancers and whether they are experiencing any symptoms. This asked about their demographic
(male or female); lifestyle choices such as whether the patient smoked, drank alcohol, or used
chewing tobacco, Supari or Paan; and whether they experienced any symptoms of head and
neck cancers or had a family history of these diseases. The survey also asked patients to input
when they had last visited their GP and dentist and whether they attend regular visits to these
healthcare professionals.
Report of Day 1 Findings
The morning of Day 2 of the conference saw The Swallows CEO, Chris
Curtis, give a presentation entitled 'Oral screening in the fight against
Head and Neck Cancer'. During this presentation, the statistics from the
Day 1 activities of oral screening were presented and the audience was
encouraged to go and be screened themselves.